New York, March 4, 2026, 09:45 EST
- Select Medical said it agreed to a $16.50-per-share take-private deal, valuing it at $3.9 billion on an enterprise-value basis.
- SEC filings show $880 million of equity backing and up to $1.0 billion of committed debt financing for the buyer group.
- The deal needs a “majority-of-the-minority” vote and U.S. regulatory clearances; the contract sets a Dec. 1, 2026 outside date.
Select Medical Holdings Corporation (NYSE: SEM) said it would be taken private for $16.50 per share in cash by a consortium led by executive chairman and co-founder Robert A. Ortenzio, senior executive vice president Martin F. Jackson and buyout firm Welsh, Carson, Anderson & Stowe. The company put the transaction at $3.9 billion on an enterprise-value basis. 1
The agreement turns an earlier, non-binding proposal from Ortenzio into a signed deal, and it sets up a vote designed to separate insiders from public holders. If it closes, Select will be delisted and stop reporting as a public company.
This matters now because the structure forces a “majority-of-the-minority” decision — meaning shareholders not affiliated with the buyers have to approve it, not just the company’s insiders. The contract also builds in the usual pressure points for deals like this: regulatory clearances and a drop-dead date.
Stallion MergerSub Corporation, a unit owned by Stallion Intermediate Corporation, will merge into Select, with Select surviving as a wholly owned subsidiary, an SEC filing showed. Shareholders who are not rolling over stock get the $16.50 cash payment, while holders who properly demand appraisal rights under Delaware law can ask a court to determine the “fair value” of their shares.
The buyer group lined up $880 million of equity financing from WCAS XIV, L.P. and debt financing commitments of up to $1.0 billion from JPMorgan Chase Bank and Wells Fargo, a Schedule 13D filing showed. The merger agreement has no financing condition. 2
Select said it expects the deal to close in mid-2026, subject to conditions including a U.S. antitrust waiting-period review under the Hart-Scott-Rodino Act and certain healthcare regulatory approvals. Initial rollover participants, who the company said own about 11.8% of the shares, agreed to vote in favor of adopting the merger agreement.
The contract sets an outside date of Dec. 1, 2026, with an automatic extension to March 1, 2027 in certain cases, the filing showed. If Select terminates to take a superior offer, it would owe a breakup fee of about $66.5 million, while the parent would owe about $133.0 million if it fails to close after conditions are met.
Select Medical operates critical illness recovery hospitals, rehabilitation hospitals and outpatient rehabilitation clinics. It had 104 critical illness recovery hospitals in 28 states, 38 rehabilitation hospitals in 15 states, and 1,917 outpatient rehabilitation clinics in 39 states and the District of Columbia as of Dec. 31, 2025, the company said — a mix that puts it alongside listed peers in rehab and therapy services such as Encompass Health and US Physical Therapy. 3
On Wall Street, Deutsche Bank analyst Justin Bowers downgraded Select Medical to hold from buy and raised his price target to $16.50, according to a note cited by Investing.com. The same report said Mizuho reiterated an outperform rating with a $17.00 target, while RBC Capital moved to a more cautious stance and cut its target to the deal price. 4
Select Medical shares were down about 0.2% at $16.23 in early trading on Wednesday, just below the cash offer price.
But the deal still has room to go wrong. The company needs approval from unaffiliated shareholders and clearance from regulators, and management-led buyouts often draw lawsuits that can slow timelines or push for better terms.
Select said it will keep operating during the merger process and expects current management to remain in place after closing. The company also said it expects existing indebtedness to remain outstanding following completion of the merger, which it said would help the consortium finance the transaction.
